Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source

Press releaseGlobeNewswire· March 19, 2026

Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights

View original at globenewswire.com

Damora Therapeutics Reports Full-Year 2025 Financial Results and Recent Corporate Highlights -- DMR-001 on track for IND or CTA submission in mid-2026, with two clinical proof-of-concept datasets expected beginning mid-2027 -- -- Strong financial position with approximately $535 million in cash and cash equivalents as…

Opening lines of the source · GlobeNewswire · short snapshot — read the full document at the original

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

DMR-001 is on track for IND or CTA submission in mid-2026
60% confidence
Cash and cash equivalents expected to fund operations into Phase 3 development of DMR-001
60% confidence
DMR-003 IND or CTA submission expected in 2027
60% confidence
DMR-002 IND or CTA submission expected in the second half of 2026
60% confidence
Two clinical proof-of-concept datasets for DMR-001 expected beginning mid-2027
60% confidence

Cited in these Via News reports

AI-Designed Drug Candidates Show Clinical Progress Across US and Canadian Trials →